FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 104 filers reported holding FATE THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.33 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $18,393,000 | +88.8% | 202,279 | -17.0% | 0.81% | +90.1% |
| Q3 2020 | $9,742,000 | +4.7% | 243,737 | -10.2% | 0.42% | +13.4% |
| Q2 2020 | $9,309,000 | +1088.9% | 271,315 | +669.7% | 0.37% | +769.8% |
| Q1 2020 | $783,000 | +12.7% | 35,250 | -0.7% | 0.04% | +43.3% |
| Q4 2019 | $695,000 | -46.8% | 35,500 | -57.8% | 0.03% | -37.5% |
| Q3 2019 | $1,306,000 | -44.3% | 84,105 | -27.2% | 0.05% | -23.8% |
| Q2 2019 | $2,345,000 | +26.3% | 115,532 | +9.3% | 0.06% | +34.0% |
| Q1 2019 | $1,856,000 | -28.3% | 105,660 | -47.6% | 0.05% | -35.6% |
| Q4 2018 | $2,588,000 | -48.9% | 201,726 | -35.1% | 0.07% | -27.7% |
| Q3 2018 | $5,060,000 | +72.2% | 310,619 | +19.8% | 0.10% | +65.6% |
| Q2 2018 | $2,939,000 | +35.3% | 259,213 | +16.5% | 0.06% | +38.6% |
| Q1 2018 | $2,172,000 | – | 222,558 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |